EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis

Biao Li iD, Jingjing Yang, Jing Li iD, Jiajia Huang, Zhiming Li

ClinicoEconomics and Outcomes Research · 2026-05 · Volume 18 · 1-12

DOI: 10.2147/ceor.s590836 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ClinicoEconomics and Outcomes Research, 2026-05. Verfasst von Biao Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen Uni…. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

brentuximab vedotin-AVDclassical Hodgkin Lymphomaincremental cost-effectiveness rationivolumab-AVDquality-adjusted life-years

Autor:innen und Institutionen

  • Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
  • Department of Clinical Nutrition, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.

ORCID-Profile: Biao Li, Jing Li

Zitieren

APA

Li, B., Yang, J., Li, J., Huang, J., & Li, Z. (2026). Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis. ClinicoEconomics and Outcomes Research, Volume 18, 1-12. https://doi.org/10.2147/ceor.s590836

Vancouver

Li B, Yang J, Li J, Huang J, Li Z. Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis. ClinicoEconomics and Outcomes Research. 2026;Volume 18:1-12. doi:10.2147/ceor.s590836

BibTeX
@article{Li2026,
  author = {Li, Biao and Yang, Jingjing and Li, Jing and Huang, Jiajia and Li, Zhiming},
  title = {Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis},
  journal = {ClinicoEconomics and Outcomes Research},
  year = {2026},
  volume = {Volume 18},
  pages = {1--12},
  doi = {10.2147/ceor.s590836}
}
Kostenlos starten →